Home > Newsletters > FDAnews Drug Daily Bulletin > Watson’s Authorized Generic Lipitor Outpaces Sales of Ranbaxy’s Version
FDAnews Drug Daily Bulletin
Jan. 18, 2012 | Vol. 9 No. 12
Watson’s Authorized Generic Lipitor Outpaces Sales of Ranbaxy’s Version
Generic versions of blockbuster cholesterol drug Lipitor raked in roughly 60 percent of sales during their first two weeks on the market, with Watson’s authorized generic beating Ranbaxy’s competitor. Watson Pharmaceuticals cornered 76 percent of generic sales with its authorized Lipitor (atorvastatin) generic in its first full week, according to IMS Health sales figures, and 55 percent during the second week, which ended Dec. 16. Ranbaxy Laboratories, which won first-filer status, gathered 24 percent of sales in the first week.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.